Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).

Autistic adults show reduced availability of a key glutamate receptor, mGlu5, across widespread brain regions.

A genetic mutation passed from mother to children in families affected by schizophrenia has now been shown to completely ...